NEW YORK--(BUSINESS WIRE)--NeoStem, Inc. (AMEX:NBS), a leading-edge healthcare company which seeks to capitalize on existing applications and anticipated breakthroughs in the burgeoning field of stem cell therapeutics, has released a new investor video detailing the promise of the hundreds of adult stem cell clinical trials currently underway to treat many of the world’s most intractable diseases. Industry analysts predict that the adult stem cell industry will generate approximately $8.5 billion by 2016, should these therapies come to market as and when expected.
